BRIDGEBIO PHARMA
BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.
BRIDGEBIO PHARMA
Industry:
Biotechnology Health Care Life Science Medical Pharmaceutical
Founded:
2014-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.bridgebio.com
Total Employee:
251+
Status:
Active
Contact:
650-391-9740
Email Addresses:
[email protected]
Total Funding:
1.95 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager WordPress Domain Not Resolving Apache
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-10-05 | Eidos Therapeutics | Eidos Therapeutics acquired by BridgeBio Pharma | 175 M USD |
Investors List
Perceptive Advisors
Perceptive Advisors investment in Series D - BridgeBio Pharma
Sequoia Capital
Sequoia Capital investment in Series D - BridgeBio Pharma
AIG Investments
AIG Investments investment in Series D - BridgeBio Pharma
Cormorant Capital
Cormorant Capital investment in Series D - BridgeBio Pharma
Aisling Capital
Aisling Capital investment in Series D - BridgeBio Pharma
Viking Global Investors
Viking Global Investors investment in Series D - BridgeBio Pharma
Hercules Capital
Hercules Capital investment in Series D - BridgeBio Pharma
Kohlberg Kravis Roberts
Kohlberg Kravis Roberts investment in Series D - BridgeBio Pharma
Janus Fund
Janus Fund investment in Series C - BridgeBio Pharma
Perceptive Advisors
Perceptive Advisors investment in Series C - BridgeBio Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-04-05 | Eidos Therapeutics | BridgeBio Pharma investment in Series B - Eidos Therapeutics | 64 M USD |
| 2018-01-30 | QED Therapeutics | BridgeBio Pharma investment in Venture Round - QED Therapeutics | 65 M USD |
| 2017-08-01 | PellePharm | BridgeBio Pharma investment in Series B - PellePharm | 20 M USD |
| 2015-04-30 | MyoKardia | BridgeBio Pharma investment in Series B - MyoKardia | 46 M USD |
| 2014-08-22 | MyoKardia | BridgeBio Pharma investment in Venture Round - MyoKardia | 10 M USD |
Official Site Inspections
http://www.bridgebio.com Semrush global rank: 2.1 M Semrush visits lastest month: 9.77 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BridgeBio Pharma"
BridgeBio | Biotechnology Company | Designing Transformative …
BridgeBio is committed to developing leaders as well as drugs. We seek individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged …See details»
BridgeBio - Crunchbase Company Profile & Funding
BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet …See details»
BridgeBio | Board of Directors
Andrew W. Lo, Ph.D. has served as a member of our Board of Directors since June 2020. Dr. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, …See details»
BridgeBio - LinkedIn
BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance ...See details»
BridgeBio | For Investors
Sep 30, 2024 BridgeBio Pharma Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat …See details»
FDA Approves Attruby - Drugs.com
PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical company focused on …See details»
Hassan, Ellis and Dachille Join Board of Directors | BridgeBio
Aug 18, 2021 “I look forward to helping BridgeBio grow into a global commercial organization that is able to reach and help patients in need around the world.” About BridgeBio Pharma, …See details»
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
Nov 23, 2024 BridgeBio plans to price the therapy at $18,759.12 for a 28-day supply. Pfizer's Vyndaqel is sold at a list price of about $268,000 a year for a recommended once-daily dose …See details»
BridgeBio - Funding, Financials, Valuation & Investors - Crunchbase
BridgeBio is registered under the ticker NASDAQ:BBIO . Their stock opened with $17.00 in its Jun 26, 2019 IPO. BridgeBio is funded by 13 investors. Blue Owl and CPP Investments are the …See details»
BridgeBio | BridgeBio Pharma Announces Collaborations with …
Oct 29, 2021 BridgeBio Pharma, Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from …See details»
BridgeBio Company Profile - Office Locations, Competitors ... - Craft
Oct 28, 2024 BridgeBio is a a clinical-stage bioteccompany focused on discovering and developing drugs for patients with grievous genetic diseases. BridgeBio has built a portfolio of …See details»
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with …
PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company …See details»
BridgeBio - Contacts, Employees, Board Members, Advisors
Organization. BridgeBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... BridgeBio has 3 board members and …See details»
BridgeBio Pharma's heart disease drug approved by FDA - Silicon …
6 days ago BridgeBio Pharma Inc. says the U.S. Food and Drug Administration (FDA) has approved the Palo Alto company's new treatment for the rare but deadly heart disease, …See details»
BridgeBio Announces Progress in Many Areas | BridgeBio
Oct 12, 2021 BridgeBio’s endless summer – Neil Kumar, Ph.D., founder and CEO, BridgeBio; Precision cardiorenal introduction – Cameron Turtle, D.Phil., ... s pipeline of over 30 …See details»
BridgeBio Oncology Therapeutics - Crunchbase
May 2, 2024 Organization. BridgeBio Oncology Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. About. ... BridgeBio Oncology …See details»
BridgeBio: Next Chapter Begins After Attruby Approval
Nov 24, 2024 Attruby’s U.S. approval triggers a $500 million cash injection for BridgeBio One of the reasons Attruby’s timely approval was critical is that it was a source of significant funding …See details»
BridgeBio | BridgeBio Pharma, Inc. and Oregon Health & Science ...
Apr 13, 2021 BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help …See details»
BridgeBio Appoints Valantine as New Board Member | BridgeBio
Oct 25, 2021 BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors. PALO ALTO, CA – October …See details»
BridgeBio Pharma, Inc. (BBIO) - Yahoo Finance
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four …See details»